Blog Financial Times: Vaccine makers race to fix vaccine supply issues January 12, 2021 GreenLight Biosciences explain to the Financial Times the vaccine supply issues for a Covid-19 vaccine. GreenLight Biosciences spoke to the Financial Times about the vaccine supply issues for the Covid-19 vaccine. An extract from the article is below: Andrey Zarur, head of GreenLight Biosciences, said ingredients stockpiled ahead of vaccine approvals would supply the first 1bn-2bn doses, but bottlenecks would emerge after that.Challenges include sourcing items ranging from DNA molecules to lipid nanoparticles — the microscopic oily droplets that deliver the vaccine’s active mRNA ingredient — he said. “Pfizer and Moderna have kicked off conversations with suppliers like Trilink, Aldevron and New England Biolabs to answer the challenge, but it will require government and deep cross-industry co-operation to make it work.” Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: Bloomberg: GreenLight Is Mass-Producing RNA to Fight Crop Pests News10NBC: GreenLight Biosciences opens new RNA facility in Rochester The New York Times: Vaccines for Africa GreenLight Biosciences opens RNA production facility for the next generation of agricultural products Jennifer Raymond welcomed as SVP, CMC and Manufacturing STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal